BridgeBio Oncology Therapeutics Inc. $(BBOT)$ announced positive preliminary safety and antitumor data from clinical studies across its three orally bioavailable small molecule RAS and PI3Kα programs. Results were presented for BBO-8520, a direct KRASG12C inhibitor, which showed a 65% objective response rate and a 66% 6-month progression-free survival in KRASG12C non-small cell lung cancer patients. Early efficacy was also observed in patients with KRASG12C and STK11 and/or KEAP1 co-mutations. Combination studies of BBO-8520 with pembrolizumab indicated promising efficacy and a differentiated safety profile. BBO-11818, a panKRAS inhibitor, demonstrated a confirmed partial response in pancreatic cancer and observed anti-tumor activity across multiple tumor types at higher dose levels. BBO-10203, a RAS-PI3Kα breaker, showed a differentiated safety profile and no observed hyperglycemia; combination studies with standard-of-care treatments in colorectal and breast cancer have been initiated, and internal combination studies are anticipated to begin this year. The data were presented during a company webcast held today.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9621195) on January 07, 2026, and is solely responsible for the information contained therein.